As shown in Supplementary Figure 4, FAT mutations significantly prolonged PFS and OS of patients with STAD or uterine corpus endometrial carcinoma and were detrimental to survival in patients with esophageal carcinoma, adrenocortical carcinoma, kidney renal papillary cell carcinoma, pancreatic adenocarcinoma, or pheochromocytoma and paraganglioma, suggesting FAT mutations were related to several tumors and might differentially affect tumor growth by regulating different biological processes. The gene discussed is FAT1; the disease is uterine corpus endometrial carcinoma.